Clinical Trials


(Novartis Signature) Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 4 - LGX818 for patients with BRAFV600 mutated tumors
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Skin | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach
Principal Investigator: Joseph Paul Eder
A Phase I, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Disease/Condition: Breast - Female | Kaposi's sarcoma | Lung | Melanoma, skin | Ovary
Principal Investigator: Joseph Kim
A Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T cells against Cancer-testis Antigens in Metastatic Melanoma
Disease/Condition: Melanoma, skin
Principal Investigator: Harriet Kluger
A Phase II Study of MK-3475 in Patients with Metastatic Melanoma or Non-Small Cell Lung Cancer with Untreated Brain Metastases
Disease/Condition: Lung | Melanoma, skin
Principal Investigator: Harriet Kluger
Expanded Access of MK-3475 in Metastatic Melanoma Patients with Limited to No Treatment Options
Principal Investigator: Mario Sznol
Phase I Study of BVD-523 in Patients with Advanced Malignancies
Disease/Condition: Melanoma, skin